IdentiGEN today announced the successful development of a novel SNP genotyping assay chemistry that confers major advantages over the market leading alternatives. 

IdentiSNP has been developed to ensure that IdentiGEN can offer its customers the most competitive low-density (1-300SNP per sample) SNP genotyping solutions globally. 

The new assay chemistry, for which patents have been filed, has been delivering transformational improvements in DNA sample analysis since it was put into production testing earlier this year. 

In particular the technology can reduce the labour cost of data scoring by more than 60%, as IdentiSNP is a single read end-point assay. The experience within IdentiGEN’s own facilities has been a dramatic reduction in the overall cost of generating of SNP genotypes.

The new SNP genotyping chemistry has been validated on multiple instrument systems including Douglas Scientific, LGC, Fluidigm and ThermoFisher systems. 

IdentiGEN Founder and Managing Director Ciaran Meghen said: “IdentiSNP is robust across a wide range of assay volumes, SNP designs and genomic templates and offers a clear alternative to the established fluorescence based genotyping assays.” 

Significant volumes of low density SNP genotyping take place across diverse segments of the global biotechnology and life science arena.  

While driven by IdentiGEN’s internal ambitions to reduce genotyping costs, opportunities to commercialise the product are now being actively pursued. 

Mr Meghen continued, “while this technology has transformed our internal cost base and will support our continued growth and development in the area of animal and meat product identification in particular, the opportunity to promote our new formulation to a wider user base is an exciting development for our business”. 

Acknowledging the need for a dedicated product team IdentiGEN has recruited experienced molecular biologists and product managers to ensure it achieves early success. 

more about identisnp